APAC Lung Cancer Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$7.38 BnPlaceholder estimate
Estimate 2025$8.20 Bn20.5% of the global market
Projected 2034$21.14 Bn 157.9%Adds $12.94 Bn over 9 forecast years
CAGR 2025–203411.1%Faster than 61% of 180 Pharmaceuticals markets here
Merck & Co., Inc., AstraZeneca, Roche, Bristol-Myers Squibb, Amgen Inc. and 1 more (see all)
Active clinical trials
1,734 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Lung Cancer Therapeutics Market Analysis Executive Summary
Lung cancer therapeutics include targeted drugs, immunotherapy, chemotherapy and antibody-drug conjugates for small-cell and non-small cell lung cancer.
Key segments of the lung Cancer Therapeutics market include drug class (Targeted Therapy, Immunotherapy and Chemotherapy) and type (Non-Small Cell Lung Cancer and Small Cell Lung Cancer).
Asia Pacific Lung Cancer Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
APAC Lung Cancer Therapeutics Market Dynamics
Market Growth Drivers
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the lung Cancer Therapeutics market. Faster approvals and new combinations are improving survival.
Opportunity
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the lung Cancer Therapeutics market.
Market Restraints
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the lung Cancer Therapeutics market, especially in low- and middle-income countries.
Competitive Landscape for Lung Cancer Therapeutics Market in APAC
The lung Cancer Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Lung Cancer Therapeutics Market in APAC
Lung Cancer Therapeutics in APAC: rules, payment and research
In some of the countries we cover here, medicines are approved by TGA (Australia)[1], NMPA (China)[2], Drug Office (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], NPRA (Malaysia)[6], Medsafe (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9] and Thai FDA (Thailand)[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[11], basic medical insurance (China)[12], the Hospital Authority (Hong Kong)[13], Ayushman Bharat PM-JAY (India)[14], public health insurance (Japan)[15], subsidised public care (Malaysia)[16], Pharmac (New Zealand)[17], PhilHealth (Philippines)[18], MediShield Life (Singapore)[19] and the Universal Coverage Scheme (Thailand)[20]. ClinicalTrials.gov lists 1,734 studies on Lung Cancer Therapeutics that are recruiting, active or about to start in APAC.[21]
[21]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for lung Cancer Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug Class
4.2 By Type
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Merck & Co.
7.2 AstraZeneca
7.3 Roche
7.4 Bristol Myers Squibb
7.5 Amgen
7.6 Johnson & Johnson
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The lung Cancer Therapeutics market can be segmented based on various criteria, including drug class, type and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Lung Cancer Therapeutics right now, from free public sources.
Clinical trials
1,734 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Lung Cancer Therapeutics market in Asia Pacific?
Placeholder estimate: about $8.20 Bn in 2025, rising to about $21.14 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Lung Cancer Therapeutics market in Asia Pacific growing?
Placeholder estimate: about 11.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Lung Cancer Therapeutics market report cover?
The report splits the market by drug class (Targeted Therapy, Immunotherapy, Chemotherapy, Antibody-Drug Conjugates), type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Lung Cancer Therapeutics market?
Key players include Merck & Co., Inc., AstraZeneca, Roche, Bristol-Myers Squibb, Amgen Inc. and Johnson & Johnson.
What is driving the Lung Cancer Therapeutics market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the lung Cancer Therapeutics market. Faster approvals and new combinations are improving survival.
How many clinical trials on Lung Cancer Therapeutics are running in Asia Pacific?
1,734 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Lung Cancer Therapeutics?
PubMed lists 50 papers on Lung Cancer Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.